Group 1 - Molson Coors Beverage, PepsiCo, and Genuine Parts will trade ex-dividend on 6/6/25, with respective dividends of $0.47, $1.4225, and $1.03 [1] - The estimated annualized yields for these companies are 3.56% for Molson Coors Beverage, 4.32% for PepsiCo, and 3.23% for Genuine Parts [4] - Following the ex-dividend date, Molson Coors Beverage shares are expected to open 0.89% lower, PepsiCo 1.08% lower, and Genuine Parts 0.81% lower [2] Group 2 - Historical dividend data can provide insights into the stability of future dividends, which is crucial for assessing potential annual yields [4] - In recent trading, Molson Coors Beverage shares decreased by about 0.2%, PepsiCo shares increased by about 0.7%, and Genuine Parts shares decreased by about 0.4% [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to alleged violations of federal securities laws, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation - The law firm is looking into claims against Elevance Health, reminding investors of the July 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that Elevance and its executives made false or misleading statements regarding the monitoring of cost trends and the adequacy of premium rates for Medicaid programs [4]. Group 2: Financial Disclosures - On July 17, 2024, Elevance disclosed an expectation of increased utilization in Medicaid, leading to a stock price decline of $32.21 per share, or 5.8% [5]. - On October 17, 2024, Elevance reported third-quarter financial results, missing EPS expectations by $1.33, or 13.7%, and lowered its EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, causing a further stock price decline of $52.61 per share, or 10.6% [6]. Group 3: Investor Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff or remain an absent class member [7]. - The firm encourages anyone with information regarding Elevance's conduct to contact them, including whistleblowers and former employees [8].

Group 1 - CoreWeave has experienced a significant stock price increase of approximately 20% over the past five days, attributed to a $7 billion data center agreement with Applied Digital, which also saw its shares rise over 63% in the same period [1][3] - The demand for artificial intelligence (AI) infrastructure is surging, and CoreWeave is strategically diversifying its operations, which is expected to benefit Nvidia, holding a 7% stake in CoreWeave [3][5] - Since its IPO in March, CoreWeave's stock has risen 275%, reaching an all-time high of $150.50 this week, with Q1 revenue increasing 420% year-over-year to $981.6 million [4][5] Group 2 - CoreWeave has partnered with IBM to provide computing power for IBM's Granite AI models and operates 250,000 Nvidia GPUs, indicating strong operational capabilities [5] - The recent momentum in CoreWeave's stock reflects solid fundamentals and suggests strong upside potential despite potential short-term volatility [5]

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial guidance and Medicaid cost trends during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors by stating they were monitoring cost trends related to the Medicaid "redetermination" process and that premium rates were sufficient to cover rising costs [4]. - It was revealed that the redetermination process led to a significant increase in the utilization of Medicaid members, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance [5]. - On July 17, 2024, Elevance disclosed an expectation of increased Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 earnings, missing EPS expectations by $1.33, or 13.7%, and lowered EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, leading to a further stock price decline of $52.61 per share, or 10.6%, closing at $444.35 [7][8].

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style S ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style S ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Key Takeaways BROS' Q1 2025 shop margin fell 40 bps to 29.4% amid rising labor, coffee tariffs and opening costs. The company expects 110 bps of full-year COGS margin pressure despite fixed coffee prices and cost controls. BROS is boosting digital efforts while aiming for 2,029 stores by 2029, despite short-term margin strain.Dutch Bros Inc. (BROS) continues to benefit from robust revenue growth and store expansion efforts. However, rising costs continue to challenge its path to higher profitability.In th ...

Core Insights - CrowdStrike Holdings, Inc. (CRWD) reported non-GAAP earnings per share of 73 cents for Q1 fiscal 2026, exceeding the Zacks Consensus Estimate by 10.61% and management's guidance of 64-66 cents, although it represented a 7.6% decline year-over-year [1][12] - Despite the earnings beat, CRWD's shares fell 6.5% in extended trading due to revenues falling short of consensus expectations [2] - The company's Q1 revenues were $1.103 billion, slightly below the Zacks Consensus Estimate of $1.105 billion, but showed a 20% year-over-year increase [2][3] Revenue Breakdown - Subscription revenues, which account for 95.2% of total revenues, increased by 20.5% year-over-year to $1.051 billion [4] - Professional services revenues rose 7.8% year-over-year to $52.67 million, contributing to the overall revenue growth [4] - As of April 30, 2025, annual recurring revenues (ARR) reached $4.4 billion, up 22% year-over-year, with a net addition of $193.8 million in the reported quarter [4][12] Customer Adoption - 48% of CRWD's subscription customers adopted six or more cloud modules, while 32% used seven or more, and 22% utilized eight or more modules as of April 30, 2025 [5] Operating Performance - Non-GAAP gross profit increased 18.5% to $857 million, with a gross margin of 78%, down 100 basis points year-over-year [6] - Non-GAAP subscription gross profit rose 19.6% to $840.8 million, while the gross margin fell 100 basis points to 80% [7] - Total non-GAAP operating expenses increased 35.6% to $656 million, representing 56% of revenues, up from 55.4% in the previous year [8][9] Profitability Metrics - Non-GAAP operating income declined 5.7% to $201.12 million, with an operating margin of 18%, down 500 basis points year-over-year [10] Cash Flow and Balance Sheet - As of January 31, 2025, CRWD had cash and cash equivalents of $4.61 billion and long-term debt of $744.36 million [13] - The company generated operating cash flow of $384.1 million and free cash flow of $279.4 million in the fiscal first quarter [13] Future Guidance - For Q2 fiscal 2026, CRWD anticipates revenues between $1.1447 billion and $1.1516 billion, with non-GAAP earnings per share expected in the range of 82-84 cents [14] - For the full fiscal year 2026, the company projects revenues between $4.7435 billion and $4.8055 billion, with non-GAAP earnings anticipated in the range of $3.44-$3.56 per share [15]